Drug treatments for Alzheimer's disease: Aricept, Exelon, Reminyl and Ebixa
ثبت نشده
چکیده
The action of Ebixa is quite different to, and more complex than, that of Aricept, Exelon and Reminyl. Ebixa blocks a messenger chemical, known as a neurotransmitter glutamate. Glutamate is released in excessive amounts when brain cells are damaged by Alzheimer's disease, which causes the brain cells to be damaged further. Ebixa can protect brain cells by blocking this release of excess glutamate.
منابع مشابه
[Therapeutic agents for Alzheimer's disease].
Currently, a handful of FDA approved drugs are commercially available to treat Alzheimer's disease (AD). Among these, Tacrine (Cognex), Donepezil (Aricept), Rivastigmine (Exelon), Galantamine (Reminyl) and Memantine (Nemenda; Forest) are either acetylcholinesterase or N-methyl-D-aspartate antagonists. These are only palliative solutions, however, and side effects remain an important concern. Cl...
متن کاملRivastigmine in the treatment of Alzheimer’s disease: an update
Alzheimer's disease is the most common form of dementia in industrialized countries. In the European Union, about 54% of dementia cases are believed to be due to Alzheimer's disease. The condition is an age-related neurodegenerative disorder characterized by multiple cognitive deficiencies, including loss of memory, judgment, and comprehension. These manifestations are accompanied by behavioral...
متن کاملUpdate on Cholinesterase Inhibitors and Treatment of Alzheimer’s Disease
The long-term studies of the cholinesterase inhibitors, Aricept (donepezil), Razadyne (galantamine) and Exelon (rivastigmine), support their ability to delay Alzheimer’s disease (AD) progression during the dementia stage by 1, 1.5, and 2.5 years respectively, which underscores the importance of early detection to optimize quality of life. Cholinesterase inhibitors reduce caregiving burden by de...
متن کاملAligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer's disease.
There are an estimated 35.6 million people with dementia worldwide [1]. More than half of these individuals have Alzheimer’s disease (AD), resulting in a progressive decline in cognition, function and communication, together with the frequent occurrence of neuropsychiatric symptoms. In addition to the enormous human costs to the individuals and their families, dementia costs the global economy ...
متن کاملComparison of the Effects of a Brand-name Drug and Its Generic Drug on the Quality of Life of Alzheimer’s Disease Patients
OBJECTIVE The pharmacological effects of generic (GE) donepezil are the same as Aricept, its brand-name counterpart. However, little is known as to whether these two drugs provide the same quality of life (QOL). The study subjects were patients with Alzheimer's disease who were taking donepezil hydrochloride tablets, and were selected by visiting either the local pharmacies or the patients' hom...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008